Atypical Hemolytic Uremic Syndrome (aHUS) is a severe renal disease which is associated with defective complement regulation caused by multiple factors. We previously described the deficiency of Factor H related proteins CFHR1 and CFHR3 as predisposing factor for aHUS. Here we identify in an extended cohort of 147 aHUS patients that 16 juvenile individuals (i.e. 11%) who either lacked the CFHR1/CFHR3 completely (n = 14) or showed extremely low CFHR1/CFHR3 plasma levels (n = 2), are positive for Factor H (CFH) autoantibodies. The binding epitopes of all 16 analyzed autoantibodies were localized to the C-terminal recognition region of Factor H, which represents a hot spot for aHUS mutations. Thus we define a novel subgroup of aHUS,
Introduction
The atypical form of hemolytic uremic syndrome (aHUS) is characterized by microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure (1) .
aHUS is associated with defective complement regulation. The complement system represents an innate immune defense system that eleminates invading microbes.
Mutations in genes coding for complement regulators Factor H (CFH), membrane cofactor protein (MCP), Factor B (CFB), C3 and Factor I (CFI) (2-9) cause impaired regulation of the alternative pathway convertase C3bBb. This results in defective local complement control on host cell surfaces (10, 11). In addition, CFH gene conversion, deletion of the complement Factor H related genes CFHR1 and CFHR3 by nonallelic homologous recombination and the presence of CFH autoantibodies have been reported in aHUS patients (12-16).
These diverse scenarios are responsible for ~50% of the reported cases, indicating that additional factors contribute to aHUS. On the surface of human cells multiple regulators control complement activation. Under physiological conditions defective function of one mutated protein is compensated by the additional regulators, which display redundant activities. This situation might explain the incomplete penetrance of the genetic mutations. We have recently shown that CFH autoantibodies of five patients bind to the C-terminus of CFH and reduce CFH-C3b interaction (16) .
In order to extend the understanding of the molecular basis of aHUS we determined the frequency of CFH autoantibodies in the Jena aHUS cohort and correlated the presence of CFH autoantibodies with CFHR1 and CFHR3 expression.
Materials and Methods

This study was approved by the Research Ethics Committee of the Friedrich Schiller
University, Jena, the University of Cologne, Germany and the Hospital for Sick Children, Toronto, Canada.
Patients
The cohort analyzed here represents an extended cohort 147 patients with atypical HUS of which 121 patients were recently reported (14) . Informations to patients are summarized (supplementary information).
Western Blot Analysis
Plasma samples of all patients (not shown) and of members of three selected families were investigated by Western blotting (14) . CFHR1 was detected using monoclonal antibody C18 and CFHR3 was detected with CFHR3 antiserum .
Identification and domain mapping of CFH autoantibodies
The binding domains of the CFH autoantibodies in CFH were determined by ELISA as described (16) . Briefly, microtiter plates (Nunc, Wiesbaden, Germany) were coated with CFH fragments (17) , incubated with plasma of the patients and CFH autoantibodies were detected with HRP-conjugated anti human IgG antibodies (Sigma-Aldrich, Taufkirchen, Germany).
Results and dicussion
Frequency of CFH autoantibodies. Here we identify by ELISA in a cohort of 147 aHUS patients 16 children (i.e. 11%) as positive for CFH autoantibodies (Table 1) .
CFH autoantibodies were completely absent in a control group of 100 healthy individuals thus indicating that CFH autoantibodies are associated with aHUS. Similar to the young age of the patients of the Jena cohort, the eight previously identified CFH autoantibody positive HUS patients (5 to 17 years) (15, 16) were also juvenile suggesting related mechanisms for autoantibody induction.
Further analyses of the CFH autoantibody positive group revealed that by means of Western blotting the patients showed either the complete absence of CFHR1 and CFHR3 in plasma (14 patients) or displayed low, barely detectable levels of CFHR1 and CFHR3 (Table 1 and data not shown). The strong correlation between the occurrence of CFH autoantibodies and absence or reduction of CFHR1/CFHR3 in plasma suggests that this deficiency represents a risk factor for CFH autoantibody formation. The mechanism how a deficiency of these plasma proteins leads to the generation of CFH autoantibodies is currently unknown and requires further investigations. The 22 CFHR1/CFHR3 deficient patients of the Jena cohort include 16 CFH autoantibody positive and six patients which have no autoantibodies to CFH. The frequency of the deficient group without CFH autoantibodies is 4% in this cohort and thus slightly higher than in the Jena and Newcastle control groups (2% each) (14) or in the Iowa-, Columbia-and Finish AMD study cohorts (2.7, 3.0 and 2.5% respectively (18) .
Concurrence of two risk factors in development of aHUS has been reported for combined mutations in either the CFI and the MCP genes (19) Thus, in each family the HUS patient was positive for CFH autoantibodies and deficient for CFHR1 and CFHR3. The chromosomal breakpoints in each case was located in the same chromosomal repeat region as recently described (14) . All 11 members of the three families, who lacked CFH autoantibodies and showed either homozygous or heterozygous CFHR1/CFHR3 deficiency were healthy. Thus, these family studies demonstrate that CFH autoantibodies develop on a background of CFHR1 and CFHR3 deficiency.
We have previously localized the binding epitope of five CFH autoantibodies, derived from aHUS patients, two of which are also part of the Jena aHUS cohort, to the C-terminus of CFH. In addition these CFH autoantibodies inhibit the regulatory function of CFH at the cell surface (16) . In order to define if this phenomenon holds true for the newly identified CFH autoantibodies their binding epitopes were also identified. 
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